专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011139738A9 THERAPIES USING ZANOLIMUMAB TO ENHANCE THE IMMUNE RESPONSE 审中-公开
标题翻译：使用ZANOLIMUMAB加强免疫反应的治疗方法
公开(公告)号：WO2011139738A9
公开(公告)日：2012-02-23
申请号：PCT/US2011034066
申请日：2011-04-27
申请人： TENX BIOPHARMA INC , ASHER NATHAN , ROSENBERG STEVEN A , SMITH GARDINER F H , SUN CHIA CHIA
发明人： NATHAN ASHER , ROSENBERG STEVEN A , SMITH GARDINER F H , SUN CHIA CHIA
IPC分类号： A61K39/395 , A61K38/20 , A61P35/00 , A61P37/00
CPC分类号： C07K16/2812 , A61K38/2013 , A61K39/39558 , A61K2300/00

2. 发明申请

WO2007131092A3 CHIMERIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE 审中-公开
标题翻译： CHIMERIC T细胞受体及相关材料及使用方法
公开(公告)号：WO2007131092A3
公开(公告)日：2008-04-03
申请号：PCT/US2007068113
申请日：2007-05-03
申请人： US GOV HEALTH & HUMAN SERV , MORGAN RICHARD A , COHEN CYRILLE J , ROSENBERG STEVEN A
发明人： MORGAN RICHARD A , COHEN CYRILLE J , ROSENBERG STEVEN A
IPC分类号： C07K19/00 , C07K14/725
CPC分类号： C07K14/7051 , C07K2319/00 , G01N33/6893
摘要： The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR.
摘要翻译：本发明提供了包含人TCR的可变区和包含非人TCR的恒定区的至少胞外结构域的恒定区的嵌合T细胞受体（TCR）及其功能变体。本发明还提供与本发明的TCR相关的多肽和蛋白质，以及编码TCR，多肽或蛋白质，重组表达载体和宿主细胞的核酸。进一步提供的是与本发明的TCR相关的药物组合物和预防或治疗疾病例如感染性疾病，宿主中的癌症，检测宿主中的病变细胞的方法的方法以及改善宿主的生物活性的方法 TCR。

3. 发明申请

WO2007037780A3 ADOPTIVE IMMUNOTHERAPY WITH ENHANCED T LYMPHOCYTE SURVIVAL 审中-公开
标题翻译：具有增强的T淋巴细胞存活的诱导型免疫治疗
公开(公告)号：WO2007037780A3
公开(公告)日：2007-08-23
申请号：PCT/US2005036407
申请日：2005-10-07
申请人： US GOV HEALTH & HUMAN SERV , MORGAN RICHARD A , ROSENBERG STEVEN A , HSU CARY
发明人： MORGAN RICHARD A , ROSENBERG STEVEN A , HSU CARY
IPC分类号： C12N5/0783
CPC分类号： C12N5/0636 , A61K2039/5156 , A61K2039/5158 , A61K2039/55527
摘要： The invention provides for compositions, e.g., pharmaceutical compositions, comprising a T lymphocyte, or a population thereof, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response. The invention further provides an isolated T lymphocyte, or population thereof, expressing at least one recombinant polynucleotide encoding the cytokine, wherein the polynucleotide comprises a non-native coding sequence encoding the cytokine. Also provided is the use of such compositions and T lymphocytes, or populations thereof, for the treatment or prevention of a medical condition e.g., cancer. A method of preparing the a T lymphocyte with enhanced T cell survival is further provided herein.
摘要翻译：本发明提供包含T淋巴细胞或其群体的组合物，例如药物组合物，其表达至少一种编码细胞因子的重组多核苷酸，所述细胞因子在免疫应答的收缩阶段期间增强T淋巴细胞的存活。本发明进一步提供了表达至少一种编码细胞因子的重组多核苷酸的分离的T淋巴细胞或其群体，其中所述多核苷酸包含编码细胞因子的非天然编码序列。还提供了这种组合物和T淋巴细胞或其群体用于治疗或预防医学病症例如癌症的用途。本文进一步提供了制备具有增强的T细胞存活的T淋巴细胞的方法。

4. 发明申请

WO0155393A9 MHC CLASS II RESTRICTED T CELL EPITOPES FROM THE CANCER ANTIGEN NY-ESO-1 审中-公开
标题翻译： MHC II类来自癌症抗原NY-ESO-1的限制性T细胞抗原
公开(公告)号：WO0155393A9
公开(公告)日：2003-03-06
申请号：PCT/US0102765
申请日：2001-01-26
申请人： US GOV HEALTH & HUMAN SERV , WANG RONG-FU , ROSENBERG STEVEN A , ZENG GANG
发明人： WANG RONG-FU , ROSENBERG STEVEN A , ZENG GANG
IPC分类号： C12N15/09 , A61K35/14 , A61K35/76 , A61K38/00 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/00 , A61K48/00 , A61P35/00 , C07K14/47 , C07K14/82 , C07K16/30 , C07K16/32 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N7/00 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/02 , C12Q1/68 , C12R1/91 , A01K67/027 , A61K38/08 , A61K38/10 , A61K38/17 , C07K7/06 , C07K7/08 , C12N15/62 , C12N15/86
CPC分类号： A61K35/17 , A01K2217/05 , A61K38/00 , A61K38/08 , A61K39/00 , A61K45/06 , A61K48/00 , A61K2039/53 , C07K7/06 , C07K14/4748 , C07K16/30 , C07K2319/00 , C12N2799/021
摘要： The present invention discloses the identification and isolation of novel MHC class II epitopes derived from the cancer antigen, NY ESO-1. The novel MHC class II epitopes from NY-EsO-1 are recognized by CD4 T lymphocytes in an HLA class II restricted manner, in particular HLA-DR or HLA-DP restricted. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
摘要翻译：本发明公开了鉴定和分离衍生自癌症抗原NY ESO-1的新型MHC II类表位。来自NY-EsO-1的新型MHC II类表位以HLA II类受限制的方式被CD4 + T淋巴细胞识别，特别是HLA-DR或HLA-DP受限制。该基因的产物是用于预防，治疗和诊断癌症患者的免疫治疗策略的有希望的候选者。

5. 发明申请

WO2008039818A3 MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 审中-公开
标题翻译：修饰的T细胞受体及相关材料和方法
公开(公告)号：WO2008039818A3
公开(公告)日：2008-06-05
申请号：PCT/US2007079487
申请日：2007-09-26
申请人： US GOV HEALTH & HUMAN SERV , MEDIGENE LTD , ROBBINS PAUL F , MORGAN RICHARD A , ROSENBERG STEVEN A , BENNETT ALAN DAVID
发明人： ROBBINS PAUL F , MORGAN RICHARD A , ROSENBERG STEVEN A , BENNETT ALAN DAVID
IPC分类号： C07K14/725 , A61K38/17 , C07K16/28 , C12Q1/02
CPC分类号： G01N33/505 , A61K38/00 , C07K14/7051 , G01N33/5091
摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4 + T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8 + T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.
摘要翻译：本发明涉及包含具有不超过3个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）在用CD4 + / T细胞表达时具有增强的识别靶细胞的能力，并且（ii）当由CD8 + T细胞表达时不表现出抗原特异性的降低。与修饰的TCR相关的多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和药物组合物也是本发明的一部分。此外，本发明涉及检测宿主中患病细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选过继免疫疗法TCR的方法。

6. 发明申请

WO9918206A3 HUMAN CANCER ANTIGEN NY ESO-1/CAG-3 AND GENE ENCODING SAME 审中-公开
标题翻译：人癌抗原NY ESO-1 / CAG-3和基因编码
公开(公告)号：WO9918206A3
公开(公告)日：1999-08-05
申请号：PCT/US9819609
申请日：1998-09-21
申请人： US GOV HEALTH & HUMAN SERV , WANG RONG FU , ROSENBERG STEVEN A
发明人： WANG RONG FU , ROSENBERG STEVEN A
IPC分类号： A61K38/00 , A61K39/00 , C07K14/47 , C12N15/12 , A01K67/027 , A61K35/14 , A61K38/08 , A61K38/10 , A61K38/17 , C07K16/18 , C12N5/08 , C12N15/11 , C12N15/86 , C12Q1/68
CPC分类号： C07K14/4748 , A01K2217/05 , A61K38/00 , A61K39/00 , C12N2799/021
摘要： The present invention discloses the identification, isolation and cloning of a gene encoding a novel cancer antigen NY ESO-1/CAG-3 and peptides thereof derived from various open reading frames from the NY ESO-1 gene. The novel cancer antigen and peptides are recognized by cytotoxic T lymphocytes in an HLA restricted manner. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.
摘要翻译：本发明公开了从NY ESO-1基因衍生自各种开放阅读框的编码新型癌抗原NY ESO-1 / CAG-3的基因及其肽的鉴定，分离和克隆。新型癌抗原和肽以HLA限制的方式被细胞毒性T淋巴细胞识别。该基因的产物是用于预防，治疗和诊断癌症患者的免疫治疗策略的有希望的候选者。

7. 发明申请

WO2015120096A3 METHODS FOR PRODUCING AUTOLOGOUS T CELLS USEFUL TO TREAT B CELL MALIGNANCIES AND OTHER CANCERS AND COMPOSITIONS THEREOF 审中-公开
标题翻译：生产用于治疗B细胞恶性肿瘤和其他癌症及其组合物的自体T细胞的方法及其组合物
公开(公告)号：WO2015120096A3
公开(公告)日：2015-11-12
申请号：PCT/US2015014520
申请日：2015-02-04
申请人： BETTER MARC , FELDMAN STEVEN A , ROSENBERG STEVEN A
发明人： BETTER MARC , FELDMAN STEVEN A , ROSENBERG STEVEN A
IPC分类号： C07K16/30 , A61K35/14
CPC分类号： C12N5/0636 , A61K35/17 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K2039/5156 , A61K2039/5158 , C07K14/7051 , C07K16/2896 , C07K2319/74 , C12N2500/90 , C12N2501/2302 , C12N2501/515 , C12N2510/00
摘要： Provided herein are methods for manufacturing T cells. In certain embodiments, methods for manufacturing T cells which express a cell surface receptor that recognizes a specific antigenic moiety on the surface of a target cell are provided. Such methods may include, but are not limited to, steps of (1 ) enriching a population of lymphocytes obtained from a donor subject; (2) stimulating the population of lymphocytes with one or more T-cell stimulating agents to produce a population of activated T cells, wherein the stimulation is performed in a closed system using serum-free culture medium; (3) transducing the population of activated T cells with a viral vector comprising a nucleic acid molecule which encodes the cell surface receptor, using a single cycle transduction to produce a population of transduced T cells, wherein the transduction is performed in a closed system using serum-free culture medium; and (4) expanding the population of transduced T cells for a predetermined time to produce a population of engineered T cells, wherein the expansion is performed in a closed system using serum-free culture medium. Also provided herein are populations of engineered T cells produced by the methods described herein and pharmaceutical compositions thereof.
摘要翻译：本文提供了用于制造T细胞的方法。在某些实施方案中，提供了用于制造表达识别靶细胞表面上的特定抗原性部分的细胞表面受体的T细胞的方法。这样的方法可以包括但不限于以下步骤：（1）富集从供体受试者获得的淋巴细胞群体; （2）用一种或多种T细胞刺激剂刺激淋巴细胞群以产生活化T细胞群，其中刺激在使用无血清培养基的封闭系统中进行; （3）用包含编码细胞表面受体的核酸分子的病毒载体转导激活的T细胞群，使用单循环转导产生转导的T细胞群，其中转导在封闭系统中进行，使用无血清培养基; 和（4）将转导的T细胞群扩增预定时间以产生工程化T细胞群，其中所述扩增在使用无血清培养基的封闭系统中进行。本文还提供了通过本文所述方法产生的工程化T细胞群及其药物组合物。

8. 发明申请

WO2009042570A3 MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 审中-公开
标题翻译：改良的T细胞受体及相关材料与方法
公开(公告)号：WO2009042570A3
公开(公告)日：2009-06-04
申请号：PCT/US2008077333
申请日：2008-09-23
申请人： US HEALTH , ROBBINS PAUL F , ROSENBERG STEVEN A , MORGAN RICHARD A
发明人： ROBBINS PAUL F , ROSENBERG STEVEN A , MORGAN RICHARD A
IPC分类号： C07K14/735
CPC分类号： C07K14/705
摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with one or more amino acid substitutions in the CDR2 and/or CDR3 regions of the alpha and/or beta chains of the TCR, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and/or CD8+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by the CD4+ T cells and/or CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of treating or preventing a disease in a host and methods of detecting a diseased cell in a host.
摘要翻译：本发明涉及一种修饰的T细胞受体（TCR），其包含在α和/或β链的CDR2和/或CDR3区域中具有一个或多个氨基酸取代的野生型（WT）TCR的氨基酸序列的TCR，其中与WT TCR相比，修饰的TCR，（i）当由CD4 + T细胞和/或CD8 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）不显示抗原的降低当由CD4 + T细胞和/或CD8 + T细胞表达时的特异性。多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。此外，本发明涉及治疗或预防宿主疾病的方法以及检测宿主中病变细胞的方法。

9. 发明申请

WO2007103901A3 AUTOLOGOUS NATURAL KILLER CELLS AND LYMPHODEPLETING CHEMOTHERAPY FOR THE TREATMENT OF CANCER 审中-公开
标题翻译：自体自然杀伤细胞和淋巴细胞治疗癌症治疗
公开(公告)号：WO2007103901A3
公开(公告)日：2008-04-10
申请号：PCT/US2007063352
申请日：2007-03-06
申请人： US GOV HEALTH & HUMAN SERV , PARKHURST MARIA R , ROSENBERG STEVEN A
发明人： PARKHURST MARIA R , ROSENBERG STEVEN A
IPC分类号： A61K35/14 , C12N5/0783
CPC分类号： C12N5/0646 , A61K38/2013 , C12N2501/23 , C12N2501/998 , C12N2502/11 , A61K2300/00
摘要： The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for a cancer antigen, e.g., a renal cell carcinoma antigen, wherein the TCR recognizes the cancer antigen in a major histocompatibility complex (MHC)-independent manner. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.
摘要翻译：本发明提供了对癌症抗原（例如肾细胞癌抗原）具有抗原特异性的分离或纯化的T细胞受体（TCR），其中TCR以主要组织相容性复合体（MHC）为依赖性识别癌抗原。还提供了相关多肽，蛋白质，核酸，重组表达载体，分离的宿主细胞，细胞群，抗体或其抗原结合部分，以及药物组合物。本发明还提供了检测宿主中癌症存在的方法以及使用本发明的TCR或相关材料治疗或预防宿主中的癌症的方法。

10. 发明申请

WO2007033213A2 EPOXY SEALER/HEALER FOR SEALING STRENGTHENING CRACKED CONCRETE 审中-公开
标题翻译：用于密封加固混凝土的EPOXY密封机/加热器
公开(公告)号：WO2007033213A2
公开(公告)日：2007-03-22
申请号：PCT/US2006035573
申请日：2006-09-12
申请人： SIKA SCHWEIZ AG , HARTMAN STUART J , ELMENDORF DAVID C , ROSENBERG STEVEN A
发明人： HARTMAN STUART J , ELMENDORF DAVID C , ROSENBERG STEVEN A
IPC分类号： E04B1/00
CPC分类号： C08G59/50 , C04B41/009 , C04B41/4853 , C04B41/63 , C04B2111/72 , E04G23/0203 , C04B28/02
摘要： An epoxy sealer/healer formulation for sealing and strengthening cracked concrete. This sealer/healer has reduced fuming and exhibits a lower exotherm.
摘要翻译：用于密封和加固裂纹混凝土的环氧树脂密封剂/治疗剂配方。这种密封剂/治疗剂减少了发烟，并且放射性降低。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式